Effectiveness of pyronaridine-artesunate against Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections: a post-hoc analysis of the CANTAM-Pyramax trial.

Saved in:
Bibliographic Details
Title: Effectiveness of pyronaridine-artesunate against Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections: a post-hoc analysis of the CANTAM-Pyramax trial.
Authors: Groger M; Institut für Tropenmedizin, University of Tubingen, Tubingen, Germany; Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Internal Medicine I, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Tona Lutete G; Unité de Pharmacologie Clinique et Pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of the Congo., Mombo-Ngoma G; Institut für Tropenmedizin, University of Tubingen, Tubingen, Germany; Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Internal Medicine I, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon., Ntamabyaliro NY; Unité de Pharmacologie Clinique et Pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of the Congo., Kahunu Mesia G; Unité de Pharmacologie Clinique et Pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of the Congo., Muena Mujobu TB; Unité de Pharmacologie Clinique et Pharmacovigilance, University of Kinshasa, Kinshasa, Democratic Republic of the Congo., Dimessa Mbadinga LB; Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon., Zoleko Manego R; Institut für Tropenmedizin, University of Tubingen, Tubingen, Germany; Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Internal Medicine I, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon., Egger-Adam D; Institut für Tropenmedizin, University of Tubingen, Tubingen, Germany., Borghini-Fuhrer I; Medicines for Malaria Venture, Geneva, Switzerland., Shin J; Shin-Poong Pharmaceutical, Seoul, Korea., Miller R; Medicines for Malaria Venture, Geneva, Switzerland., Arbe-Barnes S; Artemida Pharma, Stevenage, UK., Duparc S; Medicines for Malaria Venture, Geneva, Switzerland., Ramharter M; Institut für Tropenmedizin, University of Tubingen, Tubingen, Germany; Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine, and Department of Internal Medicine I, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: ramharter@bnitm.de.
Source: The Lancet. Microbe [Lancet Microbe] 2022 Aug; Vol. 3 (8), pp. e598-e605. Date of Electronic Publication: 2022 May 30.
Publication Type: Clinical Trial, Phase III; Clinical Trial, Phase IV; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101769019 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-5247 (Electronic) Linking ISSN: 26665247 NLM ISO Abbreviation: Lancet Microbe Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-5247
DOI:10.1016/S2666-5247(22)00092-1